Search results | Gilead Sciences

Reports

Partnering Agreements with Gilead Sciences

This report provides all the information you require to better understand Gilead Sciences and its partnering interests and activities over the past seven years.

Insights

Gilead Sciences partnering

Gilead Sciences is a top pharmaceutical company based in California, USA

Gilead Sciences: Partnering activity 2005-2013

Gilead Sciences announced over 60 partnering / licensing deals since 2005, with 20 deals in 2006 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in infectives diseases

Gilead Sciences: M&A activity 2005-2013

Gilead Sciences has also announced 9 M&A deals since 2005, with the lead deals being the acquisition of Pharmasset and Myogen

Gilead Sciences: Company Profile

return to top 50 pharma list | return to top 50 biotech list Gilead Sciences, a top biopharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Extension Denied: Gilead Sciences’ SPC Application for Combination Anti-Retrovirals

By Jonathan Ball and Camilla Sell, DMH Stallard, London The UK Intellectual Property Office (‘UKIP’) Hearing Officer’s recent decision in case BL O/006/08 (Re Gilead Sciences, Inc. 10 January 2008) has highlighted the difficulty faced by a pharmaceutical patentee seeking a Supplementary Protection Certificate (‘SPC’) for a commercially valuable combination product, relying on its basic more »

Gilead Partnering: Scientific breakthrough a product of collaboration

Gilead Sciences is a top biopharma company active in partnering, licensing and M&A in biopharmaceuticals

Gilead seeks pharma partners to bolster HIV business

Gilead Sciences is on the lookout for pharma partners for it’s HIV business and has spent $1.2 billion in two years to buy blood cancer drugs.

Life sciences’ M&A overhaul

The life sciences industry is all hauled over the innumerable and exciting M&A agreements not only involving big pharma but also small start ups

Dealmakers weekly review – February 27 2012 – Biogen Idec, Novartis, GSK, Merck & Co, YM Bioscience, Gilead, Galen

Partnering was down on the previous week in terms of number of deals, however a number of deals of financial significance were announced

Top M&A 2011:over $130 billion bet on life sciences consolidation

Analysis of data from the leading deals and alliances servicer Current Agreements, shows that the top twenty M&A deals announced in the life sciences sector during 2011 had a combined value in excess of $130 billion

Events

Sorry, your search returned no results.


Deals

Gilead Sciences to sign a generic pharma licensing deal for Hep C drug

Gilead Sciences is close to a pharma licensing deal with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.

Gilead Sciences announces $5 billion in stock repurchase financing

Gilead Sciences has authorized a repurchase of up to $5 billion of the company’s common stock.

In a M&A deal, Gilead Sciences acquired YM Biosciences for $510 million

Gilead Sciences and YM BioSciences have signed a definitive m&a agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash.

Pharma licensing approval for Gilead Sciences, HIV drug Viread in EU

A pharma licensing authorization was approved for Gilead Sciences, HIV drug, Viread by European Commission

Gilead Sciences collaborates with Indian pharma partners for antiretroviral therapy

Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

Gilead Sciences to acquire Pharmasset for $11 billion

Gilead Sciences and Pharmasset have announced that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. 

Gilead Sciences finalizes agreement with Tibotec for Prezista

Gilead Sciences has signed a license agreement with Tibotec Pharmaceuticals for the development and commercialization of a single-tablet regimen combining Prezista (darunavir) with Gilead’s Emtriva (emtricitabine); its investigational agent GS 7340, a novel prodrug of tenofovir; and cobicistat, a pharmacoenhancer. 

BMS and Gilead Sciences announce licensing agreement

Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb’s protease inhibitor REYATAZ (atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing. 

Graceway Pharmaceuticals acquires worldwide rights to GS 9191 from Gilead Sciences

Acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use.

Gilead Sciences buying CV Therapeutics for $1.4 billion

Gilead Sciences and CV Therapeutics announced the signing of a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20.00 per share in cash through a tender offer and second step merger.

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif